Yeah, advanced basal cell carcinoma is a really significant challenge, especially when patients have failed surgery. We can get patients onto hedgehog inhibitors, but there are significant side effects that go along with that. So looking to move immunotherapy earlier in the treatment profile suggests that we could potentially impact patients by maybe even decreasing the amount of surgery or treatment that they need afterwards, and in some cases, eliminate surgery if we have a complete response...
Yeah, advanced basal cell carcinoma is a really significant challenge, especially when patients have failed surgery. We can get patients onto hedgehog inhibitors, but there are significant side effects that go along with that. So looking to move immunotherapy earlier in the treatment profile suggests that we could potentially impact patients by maybe even decreasing the amount of surgery or treatment that they need afterwards, and in some cases, eliminate surgery if we have a complete response. We saw a great response rate, including a number of complete responses in this trial, suggesting that that may actually be the case, that we could eliminate less surgery, or we could reduce surgery, and we could also potentially eliminate surgery in some cases.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.